サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1565060

心臓ポンプの世界市場

Heart Pump Devices

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
心臓ポンプの世界市場
出版日: 2024年10月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

心臓ポンプの世界市場は2030年までに85億米ドルに到達

2023年に27億米ドルと推定される心臓ポンプの世界市場は、分析期間2023-2030年にCAGR 17.6%で成長し、2030年には85億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである心室補助装置（VADs）は、CAGR 19.4％を記録し、分析期間終了までに51億米ドルに達すると予測されます。大動脈内バルーンポンプ（IABPs）セグメントの成長率は、分析期間でCAGR 14.8％と推定されます。

米国市場は7億2,850万米ドル、中国はCAGR16.6％で成長予測

米国の心臓ポンプ市場は、2023年に7億2,850万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに13億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは16.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ15.9%と14.5%と予測されています。欧州では、ドイツがCAGR 11.4%で成長すると予測されています。

世界の心臓ポンプ市場- 主要動向と促進要因のまとめ

心臓ポンプが進行性心不全の治療、心臓手術のサポート、患者の生存率向上に不可欠になりつつある理由とは？

心臓ポンプは、進行した心不全の治療、心臓手術のサポート、患者の生存率向上に欠かせないものとなっています。しかし、なぜ今日、これらの機器がこれほど重要なのでしょうか？世界的に心不全の有病率が上昇する中、左室補助循環装置（LVAD）や全人工心臓（TAH）などの心臓ポンプは、薬物療法や従来の治療法では反応しなくなった患者に救命ソリューションを提供しています。これらの補助人工心臓は、機能不全に陥った心臓が血液をより効率的に送り出すのを助け、重要な臓器に十分な酸素と栄養を供給し続けられるようにすることで、心臓の機能を補助または完全に代替する上で極めて重要です。多くの末期心不全患者にとって、心臓ポンプは、心臓移植を待つ間、あるいは移植が不可能な場合の長期的な代替手段として、生命を維持するための唯一の実行可能な選択肢です。

心不全の管理だけでなく、心臓ポンプはリスクの高い心臓手術を受ける患者のサポートにも重要な役割を果たしています。このような手術では、心臓ポンプが提供する一時的な機械的循環補助が血流を確実に維持し、手術中および手術後の合併症のリスクを軽減します。また、心臓発作や心原性ショックから回復した患者など、心臓が自力で十分な血液を送り出せないような重篤な状態の患者を安定させるために使用されることも増えています。

さらに、心臓ポンプは、疲労、息切れ、体液貯留などの症状を軽減することにより、心不全患者の生活の質を著しく改善します。心臓の機能をサポートすることで、患者は日常生活をより快適に送ることができるようになり、身体的・精神的な幸福感が向上します。

技術の進歩や革新は、心臓ポンプの効率性、安全性、寿命をどのように高めているのか？

技術の進歩や革新は、心臓ポンプの効率性、安全性、寿命を大幅に向上させ、心不全患者にとってより信頼性が高く効果的なものにしています。最もインパクトのある技術革新の一つは、より小型で耐久性があり、侵襲性の低い左室補助循環装置（LVAD）の開発です。これらの新世代のLVADは、手術のリスクを少なくして植え込むように設計されており、患者により良い結果をもたらします。小型化における技術革新により、これらの装置は、以前は以前のモデルの大きさのために候補にならなかったかもしれない患者を含め、より幅広い患者に適合するようになった。また、これらの小型化された装置は、大掛かりな外科手術の必要性を最小限に抑えることで、感染症や血栓などの合併症を引き起こすことも少なくなっています。

心臓ポンプ技術のもう一つの大きな進歩は、エネルギー効率とバッテリー寿命の改善です。以前の世代の心臓ポンプは、患者が携帯しなければならない外付けバッテリーを必要とし、移動性や利便性を制限していました。今日、高度なバッテリー技術により、より長持ちする携帯用電源が可能になり、頻繁なバッテリー交換や再充電の必要性が減少しています。ワイヤレス充電技術を研究している機器もあり、これによって外部電源ケーブルが不要になり、患者の生活の質がさらに向上します。こうした改善により、心臓ポンプはより実用的で負担の少ないものとなり、患者はより自由に動き、より自立した生活を送ることができるようになります。

人工知能（AI）とデータ解析の統合も、心臓ポンプの重要なイノベーションです。AIを搭載したモニタリングシステムは、デバイスの性能と患者の生理学的パラメータを継続的に追跡し、潜在的な問題を早期に検出し、故障や悪化の兆候をヘルスケアプロバイダーに警告することができます。これらのインテリジェント・システムは、心臓ポンプが最高の効率で作動するよう、装置の設定を最適化し、リアルタイムの調整を行うのに役立ちます。AIアルゴリズムは、患者が医療介入を必要とする時期を予測し、長期的な転帰を改善し、合併症のリスクを低減することもできます。

生体適合材料もまた、心臓ポンプが著しい改善を遂げている分野です。これらの機器に使用される新素材は、心臓ポンプに関連する一般的な合併症である血液凝固（血栓症）や感染のリスクを低減します。身体の組織を模倣した高度なコーティングや素材の使用により、装置に対する免疫系の反応が最小限に抑えられ、血液希釈剤やその他の薬剤の必要性が減少します。これは患者の安全性を高めるだけでなく、消耗を減らすことで装置の寿命を延ばすことにもつながります。

遠隔監視機能は、心臓ポンプの管理方法にも変化をもたらしています。心臓ポンプを装着した患者は、コネクテッド・ヘルス・プラットフォームを通じて遠隔監視できるようになり、ヘルスケア・プロバイダーは機器の性能や患者の健康指標をリアルタイムで追跡できるようになった。これにより、潜在的な問題の早期発見が可能になり、直接診療所を訪れる頻度が減り、患者と臨床医の双方に安心感がもたらされます。さらに、遠隔モニタリングの進歩により、患者は頻繁に入院することなく、一人ひとりに合った治療や治療計画の調整を受けやすくなっています。

なぜ心臓ポンプは心不全患者の再入院を減らし、余命を延ばし、生活の質を高めるために重要なのでしょうか？

心臓ポンプは、心不全患者の再入院を減らし、余命を延ばし、生活の質を高めるために非常に重要です。心臓ポンプの価値が高い主な理由の一つは、慢性心不全患者の再入院の頻度を減らすことができることです。心不全は、心臓が血液を送り出す働きが弱くなるため、症状を繰り返し、入院を繰り返すことが多いのが特徴です。心臓ポンプは、一貫して心臓の機能をサポートし、患者の状態を安定させ、頻繁な医療介入の必要性を減らすことで、これを緩和します。これは患者のQOLを向上させるだけでなく、救急医療や病院のリソースの需要を下げることで、ヘルスケアシステムへの負担を軽減します。

寿命の延長も、心臓ポンプの大きな利点です。末期心不全患者の余命は、高度な治療法がない場合、数ヶ月から数年に制限されることが多いです。心臓ポンプ、特にLVADは、患者が心臓移植を待つ間、あるいは移植が不可能な場合の長期治療として心臓機能をサポートすることにより、生存率を著しく延長することが示されています。多くの場合、LVADを装着した患者は数年間その装置とともに生きることができ、他の治療を受けたり、より良い生活の質を維持するための時間を確保することができます。

心不全患者の生活の質を高めることは、心臓ポンプの重要な利点です。心不全は患者の日常生活を著しく制限し、疲労、息切れ、身体活動への参加能力の低下をもたらします。心臓ポンプは、血流を改善することで、これらの症状を緩和し、患者が体力とエネルギーを回復できるようにします。その結果、患者さんはより活動的な生活を送り、社会活動に参加し、より大きな自立感を得ることができるようになります。心臓ポンプを装着した患者の多くは、装着後、身体的および精神的な幸福感が著しく改善したと報告しています。

また、心臓ポンプは、心臓移植の適応とならない患者にも代替手段を提供します。年齢、合併症、ドナー心臓の有無など様々な理由で、心臓移植に適さない患者もいます。このような場合、心臓ポンプは長期的な解決策となり、心臓に機械的なサポートを提供し、患者がより長く健康的な生活を送ることを可能にします。これは、高齢の患者や、移植の候補を複雑にするような他の病状を持つ患者にとって、特に価値のあるものです。

心不全の治療における役割に加えて、心臓ポンプは心原性ショックや心臓発作など、他の心血管系疾患に関連する合併症の予防にも役立ちます。心臓ポンプは、このような重要なイベント時に機械的循環サポートを提供することで、患者を安定させ、心臓のさらなる損傷を防ぎ、全体的な生存率を向上させ、長期的な合併症のリスクを軽減します。

心臓ポンプ市場の成長を促進する要因は？

心不全の有病率の増加、心臓ポンプ技術の進歩、世界人口の高齢化、機械的循環補助の需要の高まりなど、いくつかの重要な要因が心臓ポンプ市場の急成長を促進しています。主な促進要因の1つは、世界の心不全有病率の増加です。人口が高齢化し、肥満、高血圧、糖尿病などのライフスタイル要因が一般的になるにつれて、心不全を患う人の数は着実に増加しています。このため、薬物療法や侵襲性の低い治療法では反応しなくなった患者に効果的で長期的な解決策を提供できる、心臓ポンプのような高度な治療オプションに対する大きな需要が生まれています。

心臓ポンプ技術の進歩も市場の成長を後押しする大きな要因です。より小型で耐久性に優れ、侵襲性の低い装置の開発により、心不全の重症度が低い患者や旧世代の装置では適応とならなかった患者など、より幅広い患者が心臓ポンプを利用できるようになった。このような技術改良は、患者の転帰の改善、合併症の減少、生存率の向上にもつながり、世界中のヘルスケアシステムにおける心臓ポンプの採用を後押ししています。

世界人口の高齢化も心臓ポンプ市場の成長に寄与しています。平均寿命が延び続ける中、心不全を含む加齢に伴う心血管疾患の発生率が増加しています。高齢の患者は心臓を弱らせる疾患を患う可能性が高く、心臓ポンプの有力な候補者となっています。今後数十年の間に高齢者の数が大幅に増加すると予測されており、加齢に伴う心不全の治療オプションとして心臓ポンプの需要が高まると予想されています。

また、短期的・長期的なシナリオにおける機械的循環補助に対する需要の高まりも、市場成長を後押しする要因となっています。心臓ポンプは、リスクの高い心臓手術中や心臓発作や心原性ショックから回復した患者など、クリティカルケアの現場で使用されることが増えています。心臓ポンプは患者を安定させ、回復をサポートする能力があるため、心臓専門医や心臓外科医にとって貴重なツールとなっており、病院やヘルスケア施設での採用をさらに促進しています。

また、慢性的な心臓疾患を抱える患者のQOL（生活の質）向上への注目が高まっていることも、市場を後押ししています。患者やヘルスケアプロバイダーが、延命だけでなく日常機能の向上にもつながるソリューションを求める中、心臓ポンプは心不全の管理に不可欠な選択肢とみなされています。これらの機器によってもたらされる患者の移動能力の改善、症状の軽減、全体的な生活の質の向上は、使用増加の大きな動機となっています。

さらに、政府の支援と心臓ポンプに対する規制当局の承認により、これらの救命技術へのアクセスが拡大しています。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関は、新しい心臓ポンプやイノベーションを承認するようになってきており、ヘルスケアプロバイダーや患者がこれらの技術をより広く利用できるようになってきています。このような規制当局の支援は、市場拡大を推進し、次世代心臓ポンプ技術の開発を促進する上で極めて重要です。

結論として、心臓ポンプ市場の成長は、心不全の有病率の上昇、技術の進歩、世界人口の高齢化、機械的循環補助に対する需要の増加によってもたらされます。心臓ポンプは、高度な心臓病管理のための重要なソリューションとしてヘルスケアシステムに採用され続けており、心臓ポンプは、患者の生存率を向上させ、病院での再入院を減らし、世界中の心不全患者の生活の質を高める上で、ますます重要な役割を果たすことになるでしょう。

調査対象企業の例（計 13社）

  • Abbott Laboratories
  • Abiomed, Inc.
  • Berlin Heart GmbH
  • Fresenius Medical Care AG & Co. KGaA
  • Getinge AB
  • Jarvik Heart, Inc.
  • Medtronic PLC
  • ReliantHeart, Inc.
  • SynCardia Systems, LLC
  • Teleflex Incorporated
  • Terumo Europe NV

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP12313

Global Heart Pump Devices Market to Reach US$8.5 Billion by 2030

The global market for Heart Pump Devices estimated at US$2.7 Billion in the year 2023, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 17.6% over the analysis period 2023-2030. Ventricular Assist Devices (VADs), one of the segments analyzed in the report, is expected to record a 19.4% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Intra-aortic Balloon Pumps (IABPs) segment is estimated at 14.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$728.5 Million While China is Forecast to Grow at 16.6% CAGR

The Heart Pump Devices market in the U.S. is estimated at US$728.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.9% and 14.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.4% CAGR.

Global Heart Pump Devices Market - Key Trends and Drivers Summarized

Why Are Heart Pump Devices Becoming Essential for Treating Advanced Heart Failure, Supporting Cardiac Surgeries, and Improving Patient Survival Rates?

Heart pump devices have become essential for treating advanced heart failure, supporting cardiac surgeries, and improving patient survival rates. But why are these devices so critical today? With the rising prevalence of heart failure globally, heart pump devices, such as left ventricular assist devices (LVADs) and total artificial hearts (TAHs), are providing life-saving solutions for patients who are no longer responsive to medication or traditional therapies. These devices are crucial in assisting or completely replacing the function of a failing heart by helping it pump blood more effectively, ensuring that vital organs continue to receive sufficient oxygen and nutrients. For many patients with end-stage heart failure, heart pump devices are the only viable option to sustain life while waiting for a heart transplant or as a long-term alternative when transplants are not an option.

In addition to managing heart failure, heart pump devices play a vital role in supporting patients undergoing high-risk cardiac surgeries. In such procedures, temporary mechanical circulatory support provided by heart pump devices ensures that blood flow is maintained, reducing the risk of complications during and after surgery. These devices are also being increasingly used to stabilize patients in critical conditions, such as those recovering from heart attacks or cardiogenic shock, where the heart cannot pump enough blood on its own.

Moreover, heart pump devices significantly improve the quality of life for heart failure patients by reducing symptoms like fatigue, shortness of breath, and fluid retention. By supporting the heart’s function, these devices allow patients to engage in everyday activities with greater ease, improving both physical and mental well-being.

How Are Technological Advancements and Innovations Enhancing the Efficiency, Safety, and Longevity of Heart Pump Devices?

Technological advancements and innovations are significantly enhancing the efficiency, safety, and longevity of heart pump devices, making them more reliable and effective for patients with heart failure. One of the most impactful innovations is the development of smaller, more durable, and less invasive left ventricular assist devices (LVADs). These newer-generation LVADs are designed to be implanted with fewer surgical risks and provide better outcomes for patients. Innovations in miniaturization have allowed these devices to fit into a broader range of patients, including those who previously might not have been candidates due to the size of earlier models. These smaller devices also cause fewer complications, such as infections or blood clots, by minimizing the need for extensive surgical procedures.

Another significant advancement in heart pump technology is the improvement of energy efficiency and battery life. Earlier generations of heart pump devices required external batteries that patients had to carry with them, limiting mobility and convenience. Today, advanced battery technologies allow for longer-lasting, portable power supplies, reducing the need for frequent battery changes or recharging. Some devices are even exploring wireless charging technologies, which would eliminate the need for external power cables and further enhance the patient’s quality of life. These improvements make heart pump devices more practical and less burdensome, allowing patients to move more freely and live more independently.

The integration of artificial intelligence (AI) and data analytics is another key innovation in heart pump devices. AI-powered monitoring systems can continuously track the device's performance and the patient’s physiological parameters, detecting potential issues early and alerting healthcare providers to any signs of malfunction or deterioration. These intelligent systems help optimize device settings and make real-time adjustments to ensure the heart pump is working at peak efficiency. AI algorithms can also predict when a patient may need medical intervention, improving long-term outcomes and reducing the risk of complications.

Biocompatible materials are another area where heart pump devices are seeing significant improvements. New materials used in these devices reduce the risk of blood clotting (thrombosis) and infection, which are common complications associated with heart pumps. The use of advanced coatings and materials that mimic the body’s tissues minimizes the immune system’s response to the device, reducing the need for blood thinners and other medications. This not only enhances patient safety but also extends the longevity of the device by reducing wear and tear.

Remote monitoring capabilities are also transforming the way heart pump devices are managed. Patients with heart pumps can now be monitored remotely through connected health platforms, where healthcare providers can track device performance and patient health metrics in real-time. This allows for early detection of potential issues, reduces the frequency of in-person clinic visits, and provides peace of mind to both patients and clinicians. In addition, advancements in remote monitoring are making it easier for patients to receive personalized care and adjustments to their treatment plans without the need for frequent hospital stays.

Why Are Heart Pump Devices Critical for Reducing Hospital Readmissions, Extending Life Expectancy, and Enhancing Quality of Life for Heart Failure Patients?

Heart pump devices are critical for reducing hospital readmissions, extending life expectancy, and enhancing the quality of life for heart failure patients because they provide a long-term solution for those with severe heart conditions. One of the primary reasons heart pump devices are so valuable is their ability to reduce the frequency of hospital readmissions in patients with chronic heart failure. Heart failure is often characterized by recurring symptoms, leading to repeated hospitalizations as the heart becomes less effective at pumping blood. Heart pump devices alleviate this by consistently supporting the heart’s function, stabilizing the patient’s condition, and reducing the need for frequent medical interventions. This not only improves the patient’s quality of life but also reduces the strain on healthcare systems by lowering the demand for emergency care and hospital resources.

Extending life expectancy is another significant benefit of heart pump devices. For patients with end-stage heart failure, life expectancy is often limited to a few months or years without advanced treatment options. Heart pump devices, particularly LVADs, have been shown to significantly extend survival rates by supporting heart function while patients wait for a heart transplant or as a long-term therapy when transplantation is not feasible. In many cases, patients with LVADs can live for several years with the device, providing them with more time to receive other treatments or maintain a better quality of life.

Enhancing the quality of life for heart failure patients is a key advantage of heart pump devices. Heart failure can severely limit a patient’s ability to perform daily activities, leading to fatigue, shortness of breath, and a reduced ability to participate in physical activities. Heart pump devices help alleviate these symptoms by improving blood flow, allowing patients to regain their strength and energy. This, in turn, enables them to lead more active lives, participate in social activities, and experience a greater sense of independence. Many patients with heart pump devices report significant improvements in their physical and emotional well-being after receiving the device.

Heart pump devices also offer an alternative for patients who are not eligible for heart transplants. For various reasons, including age, comorbidities, or the availability of donor hearts, some patients may not be suitable candidates for heart transplantation. In these cases, heart pump devices serve as a long-term solution, providing mechanical support to the heart and allowing patients to live longer, healthier lives. This is particularly valuable for older patients or those with other medical conditions that complicate their candidacy for a transplant.

In addition to their role in treating heart failure, heart pump devices also help prevent complications related to other cardiovascular conditions, such as cardiogenic shock or heart attacks. By providing mechanical circulatory support during these critical events, heart pump devices can stabilize patients and prevent further damage to the heart, improving overall survival rates and reducing the risk of long-term complications.

What Factors Are Driving the Growth of the Heart Pump Devices Market?

Several key factors are driving the rapid growth of the heart pump devices market, including the increasing prevalence of heart failure, advancements in heart pump technology, the aging global population, and the rising demand for mechanical circulatory support. One of the primary drivers is the growing prevalence of heart failure worldwide. As populations age and lifestyle factors such as obesity, hypertension, and diabetes become more common, the number of individuals suffering from heart failure is steadily increasing. This has created a significant demand for advanced treatment options, such as heart pump devices, that can provide effective, long-term solutions for patients who are no longer responsive to medication or less invasive therapies.

Advancements in heart pump technology are another major factor fueling the growth of the market. The development of smaller, more durable, and less invasive devices has made heart pumps more accessible to a broader range of patients, including those with less severe heart failure or those who may not have been candidates for older-generation devices. These technological improvements have also led to better patient outcomes, fewer complications, and increased survival rates, driving the adoption of heart pump devices in healthcare systems around the world.

The aging global population is also contributing to the growth of the heart pump devices market. As life expectancy continues to rise, the incidence of age-related cardiovascular conditions, including heart failure, is increasing. Older patients are more likely to suffer from conditions that weaken the heart, making them prime candidates for heart pump devices. With the number of elderly individuals projected to grow significantly over the coming decades, the demand for heart pumps as a treatment option for age-related heart failure is expected to rise.

The rising demand for mechanical circulatory support in both short-term and long-term scenarios is another factor driving market growth. Heart pump devices are increasingly being used in critical care settings, such as during high-risk cardiac surgeries or for patients recovering from heart attacks or cardiogenic shock. The ability of heart pump devices to stabilize patients and support recovery has made them a valuable tool for cardiologists and cardiac surgeons, further driving their adoption in hospitals and healthcare facilities.

The growing focus on improving the quality of life for patients with chronic heart conditions is also propelling the market. As patients and healthcare providers seek solutions that not only extend life but also enhance day-to-day functioning, heart pump devices are being viewed as an essential option for managing heart failure. The improvements in patient mobility, reduction in symptoms, and overall better quality of life provided by these devices are significant motivators for their increasing use.

Additionally, government support and regulatory approvals for heart pump devices are expanding access to these life-saving technologies. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), are increasingly approving new heart pump devices and innovations, making these technologies more widely available to healthcare providers and patients. This regulatory support is crucial for driving market expansion and fostering the development of next-generation heart pump technologies.

In conclusion, the growth of the heart pump devices market is driven by the rising prevalence of heart failure, advancements in technology, the aging global population, and the increasing demand for mechanical circulatory support. As healthcare systems continue to adopt heart pump devices as a critical solution for managing advanced heart conditions, these devices will play an increasingly vital role in improving patient survival, reducing hospital readmissions, and enhancing the quality of life for heart failure patients worldwide.

Select Competitors (Total 13 Featured) -

  • Abbott Laboratories
  • Abiomed, Inc.
  • Berlin Heart GmbH
  • Fresenius Medical Care AG & Co. KGaA
  • Getinge AB
  • Jarvik Heart, Inc.
  • Medtronic PLC
  • ReliantHeart, Inc.
  • SynCardia Systems, LLC
  • Teleflex Incorporated
  • Terumo Europe NV

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Heart Pump Devices - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cardiovascular Diseases Propels Demand for Heart Pump Devices
    • Expansion of Heart Transplant Programs Strengthens Business Case for Temporary Heart Pump Devices
    • Increasing Focus on Minimally Invasive Procedures Spurs Adoption of Percutaneous Heart Pumps
    • Growing Aging Population Expands Addressable Market Opportunity for Heart Pump Devices
    • Expansion of Chronic Heart Failure Treatment Programs Bodes Well for Market Growth
    • Future Directions: Development of Fully Implantable Artificial Hearts Accelerates Market Potential
    • Growing Popularity of Bridge-to-Transplant Therapies Expands Adoption of Heart Pumps
    • Expansion of Cardiac Centers and Specialized Clinics Generates Demand for Heart Pump Devices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Heart Pump Devices Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Heart Pump Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Heart Pump Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Heart Pump Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ventricular Assist Devices (VADs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Ventricular Assist Devices (VADs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Ventricular Assist Devices (VADs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Intra-aortic Balloon Pumps (IABPs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Intra-aortic Balloon Pumps (IABPs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Intra-aortic Balloon Pumps (IABPs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Total Artificial Heart (TAH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Total Artificial Heart (TAH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Total Artificial Heart (TAH) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Implantable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Implantable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Implantable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Extracorporeal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Extracorporeal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Extracorporeal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Bridge-to-Transplant (BTT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Bridge-to-Transplant (BTT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Bridge-to-Transplant (BTT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Bridge-to-Candidacy (BTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Bridge-to-Candidacy (BTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Bridge-to-Candidacy (BTC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Destination Therapy (DT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Destination Therapy (DT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Destination Therapy (DT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • JAPAN
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • CHINA
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • EUROPE
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Heart Pump Devices by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Heart Pump Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • FRANCE
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • GERMANY
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030

IV. COMPETITION